Apyx Medical Stock Rises 18% on Advanced Plasma Handpiece Launch
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
apyx-medicalmedical-devices
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Apyx Medical Corporation's shares surged 18% on June 19, 2026, following the commercial launch of its advanced Renuvion helium plasma handpiece for cellulite and skin laxity. The announcement, reported by finance.yahoo.com, centers on a Class II medical device cleared under FDA 510(k) regulations. This launch targets a multi-billion dollar segment of the global aesthetic energy market, which is demonstrating renewed investor appetite for growth-stage medical technology.
The aesthetic energy device market, where Apyx competes, is valued at over $6.5 billion globally. Growth has been steady, averaging 8-10% annually, driven by demand for minimally invasive cosmetic procedures. The last major competitive launch in this sub-segment was InMode's EvolveX platform in late 2024, which contributed to a 22% revenue increase for the company that fiscal year.
The current macro backdrop features stable long-term interest rates, with the 10-year Treasury yield holding around 4.2%. This environment supports risk-taking in high-growth micro-cap stocks when coupled with clear commercial catalysts. What triggered the event now is the transition from regulatory approval to commercial availability. Apyx received 510(k) clearance for this specific handpiece configuration earlier in 2026, and the stock move reflects the market pricing in the initial sales execution phase.
Apyx Medical's stock closed at $3.42 on June 19, a daily gain of $0.52. The company's market capitalization now stands at approximately $125 million, classifying it firmly as a micro-cap equity. Year-to-date, APYX is up 45%, significantly outperforming the iShares U.S. Medical Devices ETF (IHI), which is up 7% over the same period.
Apyx reported Q1 2026 revenue of $11.8 million, a 15% increase year-over-year. The firm's cash position was $18.5 million as of March 31, 2026. Gross margins for its Advanced Energy product line, which includes Renuvion, have historically ranged between 68% and 72%. The new handpiece is expected to support margin expansion through higher average selling prices compared to prior generation devices.
| Metric | Before Launch (June 18 Close) | After Launch (June 19 Close) |
|---|---|---|
| Share Price | $2.90 | $3.42 |
| Daily Volume | 450,000 | 2.1 million |
| Market Cap | ~$106M | ~$125M |
The immediate second-order effect is a capital rotation into smaller-cap aesthetic device makers. Direct competitor InMode (INMD) saw its shares trade flat on the day, indicating the market views Apyx's launch as capturing new incremental demand rather than taking significant share immediately. Suppliers of specialized medical-grade helium and generator components, such as Atlas Copco (ATCO A.ST) or smaller industrial gas firms, could see a minor uptick in B2B orders.
A key limitation is Apyx's commercial scale. The company's total 2025 revenue was $46.2 million, a fraction of InMode's $494 million. Execution risk on manufacturing ramp-up and surgeon training programs remains high. The stock's low float and micro-cap status also make it susceptible to high volatility on any news, positive or negative.
Positioning data from the prior week showed a notable increase in call option volume, suggesting some traders anticipated the launch catalyst. Short interest had been elevated at 12% of the float, indicating a potential squeeze contributed to the magnitude of the single-day move. Flow is now likely monitoring initial sell-through data to major aesthetic practice distributors.
The primary catalyst is Apyx's Q2 2026 earnings report, expected in early August. Management commentary on initial handpiece sales and updated full-year revenue guidance will be critical. The American Academy of Dermatology annual meeting in October 2026 serves as the next major venue for clinical data presentations and competitive showcase.
Key technical levels to watch include the stock's 200-day moving average, currently at $2.75, which now acts as major support. Resistance sits near the $3.80 level, which was a previous high from January 2026. If the company announces a significant distribution partnership or a large initial order before the earnings date, the stock could test that resistance.
The conditional outlook hinges on commercial execution. Should initial customer adoption meet expectations, the stock may establish a higher trading range. Conversely, any reports of supply chain delays or slower-than-expected surgeon training would likely pressure the shares back toward the pre-announcement level.
The Renuvion system uses helium plasma and radiofrequency energy to contract tissue through subdermal coagulation. It is indicated for use in dermatological and aesthetic procedures for the contraction of soft tissue, including treatment for moderate to severe cellulite. The technology aims to provide a less invasive alternative to surgical body contouring, with the newly launched handpiece designed for improved precision in treating skin laxity.
Apyx trades at a forward price-to-sales ratio of approximately 2.7x based on 2026 revenue estimates. This is a discount to the broader medical device sector average of around 4.5x but is comparable to other micro-cap commercial-stage device companies. InMode, as a larger, profitable peer, trades at a P/S ratio of 3.8x, reflecting its established commercial footprint and higher earnings margins.
Studies of small-cap medtech show that stocks typically see a positive reaction around the clearance date, but sustained outperformance depends on commercial execution. A 2023 analysis by Fazen Markets found that over 60% of companies with a market cap under $300M failed to see their stock hold clearance-day gains beyond six months if they missed their first two quarterly sales milestones post-launch.
The stock's surge reflects priced-in commercial optimism that must now be validated by quarterly sales execution.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.